Enright P L, Johnson L R, Connett J E, Voelker H, Buist A S
Mayo Clinic, Rochester, MN 55905.
Am Rev Respir Dis. 1991 Jun;143(6):1215-23. doi: 10.1164/ajrccm/143.6.1215.
The Lung Health Study is a randomized clinical trial designed to determine whether a smoking intervention program and prescription of an inhaled bronchodilator can reduce the annual rate of decline of FEV1 (FEV1 slope) in cigarette smokers with mild to moderate airflow limitation. During the recruitment period, spirometry measurements were obtained during three screening visits from 5,887 cigarette smokers 35 to 60 yr of age. To improve the statistical power of the study to detect significant differences in the FEV1 slopes among study groups, the spirometry testing protocol carefully controls for multiple factors that are known to increase intraindividual variability of FEV1 and FVC results. These factors include participant preparation, maneuver acceptability and reproducibility, technician training and performance monitoring, equipment design and calibration, and result processing. The objective of this report is to describe the success of the spirometry quality control program in minimizing the short-term intraindividual FEV1 variability. The mean difference between the FEV1 values obtained at the second and third screening visits (mean 25 days apart) was +5.7 ml in women and -14.7 ml in men, with a mean intraindividual variability of 119 ml in women and 162 ml in men, with a coefficient of variation of 5.8% for both. During only 2.1% of the test sessions were participants unable to produce three acceptable FVC maneuvers with the two best FEV1 values matching within 5% or 100 ml. Institution of site visits and technician performance monitoring was associated with improved test session quality grades and maintenance of high quality grades thereafter.
肺部健康研究是一项随机临床试验,旨在确定吸烟干预计划和吸入性支气管扩张剂的处方是否能够降低轻度至中度气流受限的吸烟者的第一秒用力呼气容积年下降率(FEV1斜率)。在招募期间,对5887名年龄在35至60岁的吸烟者进行了三次筛查访视,并进行了肺功能测定。为提高研究检测各研究组间FEV1斜率显著差异的统计效力,肺功能测试方案仔细控制了多个已知会增加FEV1和用力肺活量(FVC)结果个体内变异性的因素。这些因素包括受试者准备、操作的可接受性和可重复性、技术人员培训和性能监测、设备设计和校准以及结果处理。本报告的目的是描述肺功能质量控制计划在最小化FEV1个体内短期变异性方面的成效。在第二次和第三次筛查访视(平均间隔25天)测得的FEV1值之间,女性的平均差异为+5.7毫升,男性为-14.7毫升,女性的个体内平均变异性为119毫升,男性为162毫升,两者的变异系数均为5.8%。在仅2.1%的测试环节中,受试者无法完成三次可接受的FVC操作,且两次最佳FEV1值的匹配度未达到5%或100毫升。进行现场访视和技术人员性能监测与测试环节质量等级的改善以及此后高质量等级的维持相关。